Acute bladder retention secondary to bladder paraganglioma in an 86-year-old female: case report
DOI:
https://doi.org/10.48193/anjh6v57Keywords:
Bladder paraganglioma, catecholamines, sympathetic, bladder, neoplasmAbstract
Clinical case: an 86-year-old female comes for medical evaluation during an episode of acute urinary retention, upon medical questioning she only reffers previous events of nonspecific chills and malaise; after an urotomography is ordered, an exophytic lesion was identified in the bladder wall. Cystoscopy was performed with resection of the lesion, further inmunohistochemical analysis helped make the diagnosis of sympathetic bladder paraganglioma. Absent catecholamines were found at follow-up.
Relevance: bladder paragangliomas are extraordinarily rare, with an estimated incidence of 0.6-0.8 cases per 100,000 person-years. When located in the abdomen, it affects the organ of Zuckerkandl in 70 % of cases; the bladder is involved in only 10 % of cases of intra-abdominal paraganglioma.
Clinical implications: the cyclic secretion of catecholamines, originated by the neoplastic cells that compose the paraganglioma, causes systemic symptoms related to their activity in other organs. The clinical presentation of sympathetic bladder paragangliomas can be highly insidious, due to the wide range of local and systemic symptoms that can be observed.
Conclusions: due to the local effect of the neoplasm or its catecholamine-secreting activity, the index of suspicion for this type of neoplasm should be high and coupled with a detailed anamnesis to identify the catecholamine-related signs and/or symptoms.
References
Young WF. Paragangliomas: clinical overview. Annals of the New York Academy of Sciences. 2006;1073: 21–29. https://doi.org/10.1196/annals.1353.002.
Lee JA, Duh QY. Sporadic Paraganglioma. World Journal of Surgery. 2008;32(5): 262. https://doi.org/10.1007/s00268-007-9360-4.
Sunil V N, John K, Nawahirsha S, Iyyadurai R. Micturition syncope: a rare presentation of bladder paraganglioma. BMJ Case Reports. 2020;13(9): e235353. https://doi.org/10.1136/bcr-2020-235353.
Neumann HPH, Young WF, Eng C. Pheochromocytoma and Paraganglioma. The New England Journal of Medicine. 2019;381(6): 552–565. https://doi.org/10.1056/NEJMra1806651.
Beard CM, Sheps SG, Kurland LT, Carney JA, Lie JT. Occurrence of pheochromocytoma in Rochester, Minnesota, 1950 through 1979. Mayo Clinic Proceedings. 1983;58(12): 802–804.
Erickson D, Kudva YC, Ebersold MJ, Thompson GB, Grant CS, van Heerden JA, et al. Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients. The Journal of Clinical Endocrinology and Metabolism. 2001;86(11): 5210–5216. https://doi.org/10.1210/jcem.86.11.8034.
Boedeker CC, Neumann HPH, Maier W, Bausch B, Schipper J, Ridder GJ. Malignant Head and Neck Paragangliomas in SDHB Mutation Carriers. Otolaryngology–Head and Neck Surgery. 2007;137(1): 126–129. https://doi.org/10.1016/j.otohns.2007.01.015.
Beilan JA, Lawton A, Hajdenberg J, Rosser CJ. Pheochromocytoma of the urinary bladder: a systematic review of the contemporary literature. BMC Urology. 2013;13(1): 22. https://doi.org/10.1186/1471-2490-13-22.
Manger, William Muir, Ray W Gifford. Clinical and experimental pheochromocytoma - National Library of Medicine Institution. Blackwell Science,; 1996. https://catalog.nlm.nih.gov/discovery/fulldisplay/alma997903853406676/01NLM_INST:01NLM_INST [Accessed 6th August 2025].
Deng JH, Li HZ, Zhang YS, Liu GH. Functional paragangliomas of the urinary bladder: a report of 9 cases. Chinese Journal of Cancer. 2010;29(8): 729–734. https://doi.org/10.5732/cjc.009.10703.
Garcia-Carbonero R, Matute Teresa F, Mercader-Cidoncha E, Mitjavila-Casanovas M, Robledo M, Tena I, et al. Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomas. Clinical & Translational Oncology: Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2021;23(10): 1995–2019. https://doi.org/10.1007/s12094-021-02622-9.
Lenders JWM, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SKG, Murad MH, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. The Journal of Clinical Endocrinology and Metabolism. 2014;99(6): 1915–1942. https://doi.org/10.1210/jc.2014-1498.
Stein PP, Black HR. A simplified diagnostic approach to pheochromocytoma. A review of the literature and report of one institution’s experience. Medicine. 1991;70(1): 46–66. https://doi.org/10.1097/00005792-199101000-00004.
Bravo EL. Pheochromocytoma: new concepts and future trends. Kidney International. 1991;40(3): 544–556. https://doi.org/10.1038/ki.1991.244.
Shah MH, Goldner WS, Benson AB, Bergsland E, Blaszkowsky LS, Brock P, et al. Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN. 2021;19(7): 839–868. https://doi.org/10.6004/jnccn.2021.0032.
